Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

Clinical trial NCT04030455 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04030455
Sponsor: M.D. Anderson Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Laryngeal Squamous Cell Carcinoma Stage II Laryngeal Cancer AJCC v8 Stage III Laryngeal Cancer AJCC v8

Start date: 2019-08-07
Primary completion: 2025-09-04
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.